These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Subtype-selective antagonists of lysophosphatidic Acid receptors inhibit platelet activation triggered by the lipid core of atherosclerotic plaques. Rother E; Brandl R; Baker DL; Goyal P; Gebhard H; Tigyi G; Siess W Circulation; 2003 Aug; 108(6):741-7. PubMed ID: 12885756 [TBL] [Abstract][Full Text] [Related]
6. Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors. Ohta H; Sato K; Murata N; Damirin A; Malchinkhuu E; Kon J; Kimura T; Tobo M; Yamazaki Y; Watanabe T; Yagi M; Sato M; Suzuki R; Murooka H; Sakai T; Nishitoba T; Im DS; Nochi H; Tamoto K; Tomura H; Okajima F Mol Pharmacol; 2003 Oct; 64(4):994-1005. PubMed ID: 14500756 [TBL] [Abstract][Full Text] [Related]
7. Short-chain phosphatidates are subtype-selective antagonists of lysophosphatidic acid receptors. Fischer DJ; Nusser N; Virag T; Yokoyama K; Wang Da ; Baker DL; Bautista D; Parrill AL; Tigyi G Mol Pharmacol; 2001 Oct; 60(4):776-84. PubMed ID: 11562440 [TBL] [Abstract][Full Text] [Related]
8. Human platelets respond differentially to lysophosphatidic acids having a highly unsaturated fatty acyl group and alkyl ether-linked lysophosphatidic acids. Tokumura A; Sinomiya J; Kishimoto S; Tanaka T; Kogure K; Sugiura T; Satouchi K; Waku K; Fukuzawa K Biochem J; 2002 Aug; 365(Pt 3):617-28. PubMed ID: 11982483 [TBL] [Abstract][Full Text] [Related]
9. Initial structure-activity relationships of lysophosphatidic acid receptor antagonists: discovery of a high-affinity LPA1/LPA3 receptor antagonist. Heasley BH; Jarosz R; Lynch KR; Macdonald TL Bioorg Med Chem Lett; 2004 Jun; 14(11):2735-40. PubMed ID: 15125924 [TBL] [Abstract][Full Text] [Related]
10. Lysophosphatidylmethanol is a pan lysophosphatidic acid receptor agonist and is produced by autotaxin in blood. Endo T; Kano K; Motoki R; Hama K; Okudaira S; Ishida M; Ogiso H; Tanaka M; Matsuki N; Taguchi R; Kanai M; Shibasaki M; Arai H; Aoki J J Biochem; 2009 Aug; 146(2):283-93. PubMed ID: 19416959 [TBL] [Abstract][Full Text] [Related]
11. Lysophosphatidic acids, cyclic phosphatidic acids and autotaxin as promising targets in therapies of cancer and other diseases. Gendaszewska-Darmach E Acta Biochim Pol; 2008; 55(2):227-40. PubMed ID: 18560605 [TBL] [Abstract][Full Text] [Related]
16. A novel series of 2-pyridyl-containing compounds as lysophosphatidic acid receptor antagonists: development of a nonhydrolyzable LPA3 receptor-selective antagonist. Heasley BH; Jarosz R; Carter KM; Van SJ; Lynch KR; Macdonald TL Bioorg Med Chem Lett; 2004 Aug; 14(15):4069-74. PubMed ID: 15225728 [TBL] [Abstract][Full Text] [Related]
17. Dioleoyl phosphatidic acid induces morphological changes through an endogenous LPA receptor in C6 glioma cells. Chang YJ; Kim YL; Jo JY; Kyeok K; Kim HL; Im DS Arch Pharm Res; 2008 May; 31(5):628-33. PubMed ID: 18481020 [TBL] [Abstract][Full Text] [Related]
18. Fatty alcohol phosphates are subtype-selective agonists and antagonists of lysophosphatidic acid receptors. Virag T; Elrod DB; Liliom K; Sardar VM; Parrill AL; Yokoyama K; Durgam G; Deng W; Miller DD; Tigyi G Mol Pharmacol; 2003 May; 63(5):1032-42. PubMed ID: 12695531 [TBL] [Abstract][Full Text] [Related]